Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 2, 2012, Pages 147-153

  Yin, Haitao ^a   Guo, Rui ^b   Xu, Yong ^c   Zheng, Yulong ^c   Hou, Zhibo ^a   Dai, Xinzheng ^d   Zhang, Zhengdong ^d   Zheng, Donghui ^c   Xu, Hua'e ^d  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

curcumin; docetaxel; lung cancer; synergistic interaction

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; DOCETAXEL; TAXOID;

ANIMAL; ARTICLE; CHINESE MEDICINE; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CURCUMIN; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, NUDE; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CURCUMA LONGA;

EID: 84863040534     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr106     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun M. Cancer statistics 2009. CA Cancer J Clin 2009, 59: 225-249.
2. American Cancer Society. Cancer Facts and Figures 2008. Atlanta: American Cancer Society, 2008.
3. Saloustros E and Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008, 8: 1207-1222.
4. Saloustros E, Mavroudis D and Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 2008, 9: 2603-2616.
5. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL and Herlyn M, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008, 14: 230-239.
6. NCCN clinical practice guidelines in oncology: Lung cancer. 2011.
7. Baker J, Ajani J, Scotte F, Winther D, Martin M, Aapro MS and von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2008, 12: 253-268.
8. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E and Dicato M, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005, 223: 181-190.
9. Aggarwal BB, Kumar A and Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 2003, 23: 363-398.
10. Phillips JM, Clark C, Herman-Ferdinandez L, Moore-Medlin T, Rong X, Gill JR and Clifford JL, et al. Curcumin inhibits skin squamous cell car-cinoma tumor growth in vivo. Otolaryngol Head Neck Surg 2011, 145: 58-63.
11. Wong TF, Takeda T, Li B, Tsuiji K, Kitamura M, Kondo A and Yaegashi N. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol 2011, 122: 141-148.
12. Wang Y, Rishi AK, Wu W, Polin L, Sharma S, Levi E and Albelda S, et al. Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Mol Cell Biochem 2011, 357: 83-94.
13. Qian H, Yang Y and Wang X. Curcumin enhanced adriamycin-induced human liver-derived hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci 2011, 43: 125-131.
14. Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J and Fuchs JR, et al. Sensitization of head and neck cancer to Cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg 2011, 137: 499-507.
15. Wang T, Wei J, Qian X, Ding Y, Yu L and Liu B. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 2008, 262: 214-222.
16. Wei J, Liu B, Wang L, Qian X, Ding Y and Yu L. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. Cancer Chemother Pharmacol 2007, 60: 703-711.
17. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22: 27-55.
18. Jin ZJ. Addition in drug combination. Acta Pharmacol Sin 1980, 1: 70.
19. Barret JM, Etievant C and Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000, 45: 471-476.
20. Gu H, Rao S, Zhao J, Wang J, Mu R, Rong J and Tao L, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 2009, 135: 1777-1782.
21. Garg AK, Buchholz TA and Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 2005, 7: 1630-1647.
22. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ and Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005, 65: 8455-8460.
23. Chen Q, Wang Y, Xu K, Lu G, Ying Z, Wu L and Zhan J, et al. Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Oncol Rep 2010, 23: 397-403.